Skip to main content
Top
Published in: International Urology and Nephrology 9/2019

Open Access 01-09-2019 | Peritoneal Dialysis | Nephrology - Original Paper

Dialysate copeptin and peritoneal transport in incident peritoneal dialysis patients

Authors: Maciej Fijałkowski, Krzysztof Safranow, Bengt Lindholm, Kazimierz Ciechanowski, Anna Maria Muraszko, Barbara Dołęgowska, Katarzyna Dołęgowska, Edyta Golembiewska

Published in: International Urology and Nephrology | Issue 9/2019

Login to get access

Abstract

Purpose

Systemic and intraperitoneal inflammation are characteristic features of patients with end-stage renal disease undergoing chronic peritoneal dialysis (PD). Arginine vasopressin (AVP) and its surrogate marker copeptin play important roles in many pathophysiological processes in chronic kidney disease. The aim of this study was to assess if copeptin concentrations in plasma and dialysate were related to peritoneal transport parameters and residual renal function (RRF) in incident PD patients.

Methods

In 37 clinically stable incident PD patients (mean age 50 years, 68% women, 32% diabetes), a 4 h peritoneal equilibration test (PET) was performed 4–6 weeks after the onset of PD. Plasma (at 2 h of PET) and dialysate (at 4 h) concentrations of copeptin, high-sensitivity C-reactive protein and interleukin-6 (IL-6) were determined.

Results

Plasma (80.7 ± 37.3 pg/mL) and dialysate (33.2 ± 18.0 pg/mL) concentrations of copeptin were correlated (Rs = 0.52, p = 0.001). Plasma and dialysate copeptin concentrations were negatively correlated with renal function as assessed by renal Kt/V (Rs = − 0.38; p = 0.021 and Rs = − 0.33; p = 0.047, respectively). At PET, dialysate copeptin negatively correlated with D/P creatinine (Rs = − 0.35, p = 0.033), and positively with D/D0 glucose (Rs = 0.33, p = 0.045) and ultrafiltration (Rs = 0.37, p = 0.024). Multivariate analysis showed that low dialysate copeptin (β = –0.30, p = 0.049) and high dialysate IL-6 (β = + 0.40, p = 0.012) were independent determinants of higher D/P creatinine.

Conclusions

Dialysate copeptin was negatively associated with D/P creatinine in incident PD patients suggesting a potential influence of copeptin or AVP on peritoneal solute transport rate that might involve vasoactive mechanisms.
Literature
1.
go back to reference Allawi AAD (2018) Malnutrition, inflamation and atherosclerosis (MIA syndrome) in patients with end stage renal disease on maintenance hemodialysis (a single centre experience). Diabetes Metab Syndr 12(2):91–97CrossRefPubMed Allawi AAD (2018) Malnutrition, inflamation and atherosclerosis (MIA syndrome) in patients with end stage renal disease on maintenance hemodialysis (a single centre experience). Diabetes Metab Syndr 12(2):91–97CrossRefPubMed
2.
3.
go back to reference Dai L et al (2017) End-stage renal disease, inflammation and cardiovascular outcomes. Contrib Nephrol 191:32–43CrossRefPubMed Dai L et al (2017) End-stage renal disease, inflammation and cardiovascular outcomes. Contrib Nephrol 191:32–43CrossRefPubMed
4.
go back to reference Blake PG (2001) Integrated end-stage renal disease care: the role of peritoneal dialysis. Nephrol Dial Transpl 16(Suppl 5):61–66CrossRef Blake PG (2001) Integrated end-stage renal disease care: the role of peritoneal dialysis. Nephrol Dial Transpl 16(Suppl 5):61–66CrossRef
5.
6.
go back to reference Martikainen TA et al (2005) Glucose-free dialysis solutions: inductors of inflammation or preservers of peritoneal membrane? Perit Dial Int 25(5):453–460PubMed Martikainen TA et al (2005) Glucose-free dialysis solutions: inductors of inflammation or preservers of peritoneal membrane? Perit Dial Int 25(5):453–460PubMed
7.
go back to reference Twardowski ZJ (1989) Clinical value of standardized equilibration tests in CAPD patients. Blood Purif 7(2–3):95–108CrossRefPubMed Twardowski ZJ (1989) Clinical value of standardized equilibration tests in CAPD patients. Blood Purif 7(2–3):95–108CrossRefPubMed
8.
go back to reference Cho Y et al (2014) Dialysate interleukin-6 predicts increasing peritoneal solute transport rate in incident peritoneal dialysis patients. BMC Nephrol 15:8CrossRefPubMedPubMedCentral Cho Y et al (2014) Dialysate interleukin-6 predicts increasing peritoneal solute transport rate in incident peritoneal dialysis patients. BMC Nephrol 15:8CrossRefPubMedPubMedCentral
9.
go back to reference Holwerda DA (1972) A glycopeptide from the posterior lobe of pig pituitaries. I. Isolation and characterization. Eur J Biochem 28(3):334–339CrossRefPubMed Holwerda DA (1972) A glycopeptide from the posterior lobe of pig pituitaries. I. Isolation and characterization. Eur J Biochem 28(3):334–339CrossRefPubMed
10.
go back to reference Morgenthaler NG et al (2006) Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 52(1):112–119CrossRefPubMed Morgenthaler NG et al (2006) Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 52(1):112–119CrossRefPubMed
11.
go back to reference Christ-Crain M, Fenske W (2016) Copeptin in the diagnosis of vasopressin-dependent disorders of fluid homeostasis. Nat Rev Endocrinol 12(3):168–176CrossRefPubMed Christ-Crain M, Fenske W (2016) Copeptin in the diagnosis of vasopressin-dependent disorders of fluid homeostasis. Nat Rev Endocrinol 12(3):168–176CrossRefPubMed
12.
go back to reference Enhörning S, Christensson A, Melander O (2019) Plasma copeptin as a predictor of kidney disease. Nephrol Dial Transpl 34(1):74–82CrossRef Enhörning S, Christensson A, Melander O (2019) Plasma copeptin as a predictor of kidney disease. Nephrol Dial Transpl 34(1):74–82CrossRef
14.
go back to reference Golembiewska E et al (2017) Prognostic value of copeptin in chronic kidney disease: from general population to end-stage renal disease. Curr Protein Pept Sci 18(12):1232–1243CrossRefPubMed Golembiewska E et al (2017) Prognostic value of copeptin in chronic kidney disease: from general population to end-stage renal disease. Curr Protein Pept Sci 18(12):1232–1243CrossRefPubMed
15.
go back to reference Bhandari SS et al (2009) Gender and renal function influence plasma levels of copeptin in healthy individuals. Clin Sci (Lond) 116(3):257–263CrossRef Bhandari SS et al (2009) Gender and renal function influence plasma levels of copeptin in healthy individuals. Clin Sci (Lond) 116(3):257–263CrossRef
16.
go back to reference Niemczyk S et al (2018) Copeptin blood content as a diagnostic marker of chronic kidney disease. Adv Exp Med Biol 1096:83–91CrossRefPubMed Niemczyk S et al (2018) Copeptin blood content as a diagnostic marker of chronic kidney disease. Adv Exp Med Biol 1096:83–91CrossRefPubMed
18.
go back to reference Zittema D et al (2017) Copeptin, a surrogate marker for arginine vasopressin, is associated with disease severity and progression in IgA nephropathy patients. Nephrol Dial Transpl 32(suppl_1):146–153 Zittema D et al (2017) Copeptin, a surrogate marker for arginine vasopressin, is associated with disease severity and progression in IgA nephropathy patients. Nephrol Dial Transpl 32(suppl_1):146–153
19.
go back to reference Boertien WE et al (2012) Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease. Nephrol Dial Transpl 27(11):4131–4137CrossRef Boertien WE et al (2012) Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease. Nephrol Dial Transpl 27(11):4131–4137CrossRef
20.
go back to reference Corradi V et al (2016) Copeptin levels and kidney function in ADPKD: case-control study. Clin Nephrol 86(9):147–153CrossRefPubMed Corradi V et al (2016) Copeptin levels and kidney function in ADPKD: case-control study. Clin Nephrol 86(9):147–153CrossRefPubMed
21.
go back to reference Meijer E et al (2009) Copeptin, a surrogate marker of vasopressin, is associated with accelerated renal function decline in renal transplant recipients. Transplantation 88(4):561–567CrossRefPubMed Meijer E et al (2009) Copeptin, a surrogate marker of vasopressin, is associated with accelerated renal function decline in renal transplant recipients. Transplantation 88(4):561–567CrossRefPubMed
23.
go back to reference Artunc F et al (2014) Plasma concentrations of the vasoactive peptide fragments mid-regional pro-adrenomedullin, C-terminal pro-endothelin 1 and copeptin in hemodialysis patients: associated factors and prediction of mortality. PLoS One 9(1):e86148CrossRefPubMedPubMedCentral Artunc F et al (2014) Plasma concentrations of the vasoactive peptide fragments mid-regional pro-adrenomedullin, C-terminal pro-endothelin 1 and copeptin in hemodialysis patients: associated factors and prediction of mortality. PLoS One 9(1):e86148CrossRefPubMedPubMedCentral
24.
go back to reference Ettema EM et al (2015) Changes in plasma copeptin levels during hemodialysis: are the physiological stimuli active in hemodialysis patients? PLoS One 10(5):e0127116CrossRefPubMedPubMedCentral Ettema EM et al (2015) Changes in plasma copeptin levels during hemodialysis: are the physiological stimuli active in hemodialysis patients? PLoS One 10(5):e0127116CrossRefPubMedPubMedCentral
25.
go back to reference Ettema EM et al (2017) The effect of renal function and hemodialysis treatment on plasma vasopressin and copeptin levels. Kidney Int Rep 2(3):410–419CrossRefPubMedPubMedCentral Ettema EM et al (2017) The effect of renal function and hemodialysis treatment on plasma vasopressin and copeptin levels. Kidney Int Rep 2(3):410–419CrossRefPubMedPubMedCentral
27.
go back to reference Pecoits-Filho R et al (2006) Systemic and intraperitoneal interleukin-6 system during the first year of peritoneal dialysis. Perit Dial Int 26(1):53–63PubMed Pecoits-Filho R et al (2006) Systemic and intraperitoneal interleukin-6 system during the first year of peritoneal dialysis. Perit Dial Int 26(1):53–63PubMed
28.
go back to reference Oh KH et al (2010) Intra-peritoneal interleukin-6 system is a potent determinant of the baseline peritoneal solute transport in incident peritoneal dialysis patients. Nephrol Dial Transpl 25(5):1639–1646CrossRef Oh KH et al (2010) Intra-peritoneal interleukin-6 system is a potent determinant of the baseline peritoneal solute transport in incident peritoneal dialysis patients. Nephrol Dial Transpl 25(5):1639–1646CrossRef
29.
go back to reference Nemenoff RA (1998) Vasopressin signaling pathways in vascular smooth muscle. Front Biosci 3:d194–d207CrossRefPubMed Nemenoff RA (1998) Vasopressin signaling pathways in vascular smooth muscle. Front Biosci 3:d194–d207CrossRefPubMed
30.
go back to reference Spatz M et al (1994) Vasoconstrictive peptides induce endothelin-1 and prostanoids in human cerebromicrovascular endothelium. Am J Physiol 266(3 Pt 1):C654–C660CrossRefPubMed Spatz M et al (1994) Vasoconstrictive peptides induce endothelin-1 and prostanoids in human cerebromicrovascular endothelium. Am J Physiol 266(3 Pt 1):C654–C660CrossRefPubMed
31.
go back to reference Kocyigit I et al (2016) Vasopressin-related copeptin is a novel predictor of early endothelial dysfunction in patients with adult polycystic kidney disease. BMC Nephrol 17(1):196CrossRefPubMedPubMedCentral Kocyigit I et al (2016) Vasopressin-related copeptin is a novel predictor of early endothelial dysfunction in patients with adult polycystic kidney disease. BMC Nephrol 17(1):196CrossRefPubMedPubMedCentral
32.
33.
go back to reference Zakaria ER et al (2008) Vasoactive components of dialysis solution. Perit Dial Int 28(3):283–295PubMedCentral Zakaria ER et al (2008) Vasoactive components of dialysis solution. Perit Dial Int 28(3):283–295PubMedCentral
Metadata
Title
Dialysate copeptin and peritoneal transport in incident peritoneal dialysis patients
Authors
Maciej Fijałkowski
Krzysztof Safranow
Bengt Lindholm
Kazimierz Ciechanowski
Anna Maria Muraszko
Barbara Dołęgowska
Katarzyna Dołęgowska
Edyta Golembiewska
Publication date
01-09-2019
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 9/2019
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-019-02191-5

Other articles of this Issue 9/2019

International Urology and Nephrology 9/2019 Go to the issue